Showing results (21-30 of 53) with videos related to

Sort By:
Pageof 6
Clinical and Translational Radiation Oncology|May 19, 2023
Stereotactic body radiotherapy for extra-cranial oligoprogressive or oligorecurrent small-cell lung cancerAntonin Levy, Jonathan Khalifa, Etienne Martin, et al.
Cardiovascular and Interventional Radiology|November 7, 2019
Correction to: Focus on Recommendations for the Management of Non-small Cell Lung CancerPernelle Lavaud, Benjamin Besse, Thierry de Baere, et al.
NPJ Precision Oncology|July 17, 2021
Circulating tumor cell copy-number heterogeneity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitorsMarianne Oulhen, Patrycja Pawlikowska, Tala Tayoun, et al.
European Journal of Cancer (Oxford, England : 1990)|February 9, 2023
Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with advanced non-small cell lung cancerAdrien Rousseau, Marco Tagliamento, Edouard Auclin, et al.
Frontiers in Oncology|June 7, 2021
Treatments Outcomes in Histological Variants and Non-Urothelial Bladder Cancer: Results of a Multicenter Retrospective StudyNicolas Epaillard, Pauline Parent, Yohann Loriot, et al.
JAMA Oncology|April 9, 2026
Outcomes and Treatments of Patients With Non-Small Cell Lung Cancer Who Received PembrolizumabAdrien Rousseau, Stéphanie Foulon, David Planchard, et al.
Therapeutic Advances in Urology|March 1, 2024
Carboplatin in metastatic castration-resistant prostate cancer patients with molecular alterations of the DNA damage repair pathway: the PRO-CARBO phase II trialElodie Coquan, Nicolas Penel, Justine Lequesne, et al.
Journal for Immunotherapy of Cancer|January 8, 2025
Durvalumab and tremelimumab in combination with metronomic oral vinorelbine for recurrent advanced cervical cancer: an open-label phase I/II studyJean-Sébastien Frenel, Laurent Mathiot, Claire Cropet, et al.
Drugs|May 5, 2022
PARP Inhibition, a New Therapeutic Avenue in Patients with Prostate CancerRonan Flippot, Anna Patrikidou, Mihaela Aldea, et al.
The Lancet Regional Health. Europe|July 23, 2024
Impact of pembrolizumab treatment duration on overall survival and prognostic factors in advanced non-small cell lung cancer: a nationwide retrospective cohort studyAdrien Rousseau, Stefan Michiels, Noémie Simon-Tillaux, et al.
Pageof 6